Topcon
7732
TEMONA
3985
Forside
2330
Okamoto Glass
7746
Delta-Fly Pharma
4598
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -3.02%63.12B | 9.39%17.48B | 0.62%16.43B | -11.59%15.32B | -10.08%13.88B | 3.84%65.08B | 0.05%15.98B | 0.14%16.33B | 8.45%17.32B | 7.13%15.44B |
Cost of revenue | -4.58%49.73B | 1.31%13.07B | -3.96%12.62B | -10.31%12.46B | -4.96%11.58B | 11.00%52.12B | 5.66%12.9B | 7.65%13.14B | 16.91%13.89B | 14.39%12.19B |
Gross profit | 3.28%13.39B | 43.29%4.41B | 19.39%3.82B | -16.76%2.86B | -29.30%2.3B | -17.55%12.96B | -18.18%3.08B | -22.16%3.2B | -16.11%3.43B | -13.44%3.25B |
Operating expense | -3.96%11.31B | -0.56%2.86B | -3.01%2.84B | -9.08%2.73B | -3.01%2.87B | 6.14%11.77B | 0.63%2.88B | 3.39%2.93B | 9.83%3.01B | 11.19%2.96B |
Selling and administrative expenses | -3.96%11.31B | ---- | ---- | ---- | ---- | 6.14%11.77B | ---- | ---- | ---- | ---- |
-Selling and marketing expense | -2.74%4.08B | ---- | ---- | ---- | ---- | 0.60%4.2B | ---- | ---- | ---- | ---- |
-General and administrative expense | -4.63%7.22B | ---- | ---- | ---- | ---- | 9.48%7.57B | ---- | ---- | ---- | ---- |
Operating profit | 75.00%2.08B | 674.50%1.55B | 261.25%979M | -71.06%123M | -295.89%-572M | -74.32%1.19B | -77.83%200M | -78.78%271M | -68.59%425M | -73.33%292M |
Net non-operating interest income (expenses) | -25.66%-284M | -11.29%-69M | -26.67%-76M | -50.00%-78M | -17.31%-61M | -3.67%-226M | -12.73%-62M | -13.21%-60M | 1.89%-52M | 8.77%-52M |
Non-operating interest income | 10.00%11M | 150.00%5M | 0.00%4M | -50.00%1M | -50.00%1M | 42.86%10M | 0.00%2M | 300.00%4M | -33.33%2M | 100.00%2M |
Non-operating interest expense | 25.00%295M | 15.63%74M | 25.00%80M | 46.30%79M | 14.81%62M | 4.89%236M | 12.28%64M | 18.52%64M | -3.57%54M | -6.90%54M |
Net investment income | 20.88%301M | 384.62%63M | 158.82%44M | 10.68%114M | -31.03%80M | 77.86%249M | -83.54%13M | -22.73%17M | 186.11%103M | 3,766.67%116M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 716.00%408M | 0 | 247.06%50M | 5,100.00%50M | ||||||
Income from associates and other participating interests | -91.67%3M | 122.22%2M | 0.00%1M | -103.70%-1M | -94.12%1M | -34.55%36M | -175.00%-9M | -94.12%1M | 68.75%27M | 70.00%17M |
Special income (charges) | 87.90%-124M | -112.50%-68M | 42.86%-16M | 97.74%-21M | 45.71%-19M | -4,980.95%-1.03B | -169.57%-32M | -170.00%-28M | -930.36%-930M | 80.23%-35M |
Less:Other special charges | -75.73%58M | -93.75%2M | -42.86%16M | -85.42%21M | -45.71%19M | 1,238.10%239M | 169.57%32M | 170.00%28M | 228.57%144M | -80.23%35M |
Less:Write off | -91.60%66M | --66M | ---- | ---- | ---- | --786M | --0 | --0 | ---- | ---- |
Other non-operating income (expenses) | 30.43%-32M | -105.56%-37M | 65.22%-8M | 325.00%18M | -266.67%-5M | 88.86%-46M | 51.35%-18M | 81.60%-23M | 96.79%-8M | 250.00%3M |
Income before tax | 945.98%2.34B | 925.00%1.44B | 649.72%1.33B | 136.41%158M | -269.21%-577M | -94.64%224M | -85.23%140M | -84.92%177M | -136.66%-434M | -60.94%341M |
Income tax | 155.47%700M | 200.74%406M | 244.55%379M | 175.27%70M | -227.05%-155M | -75.94%274M | -38.91%135M | -60.14%110M | -124.41%-93M | -53.26%122M |
Net income | 3,451.02%1.64B | 17,050.00%1.03B | 1,313.43%947M | 125.81%88M | -292.69%-422M | -101.61%-49M | -99.17%6M | -92.54%67M | -142.47%-341M | -64.16%219M |
Net income continuous operations | 3,386.00%1.64B | 20,480.00%1.03B | 1,314.93%948M | 125.81%88M | -292.69%-422M | -101.64%-50M | -99.31%5M | -92.54%67M | -142.47%-341M | -64.22%219M |
Noncontrolling interests | 31.09%468M | 811.76%155M | 153.73%170M | -42.48%88M | -54.17%55M | -34.62%357M | -81.91%17M | -66.16%67M | 14.18%153M | 0.00%120M |
Net income attributable to the company | 388.45%1.17B | 7,391.67%875M | 77,600.00%777M | 99.80%-1M | -586.73%-477M | -116.33%-407M | -101.90%-12M | -99.86%1M | -173.73%-494M | -80.00%98M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 388.45%1.17B | 7,391.67%875M | 77,600.00%777M | 99.80%-1M | -586.73%-477M | -116.33%-407M | -101.90%-12M | -99.86%1M | -173.73%-494M | -80.00%98M |
Gross dividend payment | ||||||||||
Basic earnings per share | 393.31%122.81 | 6,040.91%91.49 | 24,751.52%81.35 | 99.86%-0.07 | -617.18%-49.96 | -117.10%-41.87 | -102.48%-1.54 | -100.48%-0.33 | -175.45%-49.66 | -79.96%9.66 |
Diluted earnings per share | 393.31%122.81 | 6,037.15%91.4321 | 24,703.36%81.1911 | 99.80%-0.1046 | -617.18%-49.96 | -117.10%-41.87 | -102.48%-1.54 | -100.48%-0.33 | -178.52%-51.6834 | -79.96%9.66 |
Dividend per share | -18.75%65 | 12.50%45 | 0 | -50.00%20 | 0 | 0.00%80 | -11.11%40 | 0 | 14.29%40 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |